Zinc acetate - Teva Pharmaceuticals

Drug Profile

Zinc acetate - Teva Pharmaceuticals

Alternative Names: Galzin; Wilzin; Zinc acetate dihydrate - Teva Pharmaceuticals

Latest Information Update: 14 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lemmon
  • Developer Orphan Europe; Teva Pharmaceuticals USA
  • Class Acetates; Antiacnes; Antidiarrhoeals; Heavy metals
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatolenticular degeneration

Most Recent Events

  • 13 Aug 2015 Launched for Wilson's disease in Slovenia, Lithuania, Slovakia and Latvia (PO) before August 2015
  • 30 Apr 2015 Launched for Wilson's disease in Greece (PO) before April 2015
  • 03 Feb 2015 Launched for Wilson's disease in Austria (PO) before February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top